Mass. approves $1B biotech project

Massachusetts officials have green-lighted a $1 billion, five-building biotech center near Kendall Square in Cambridge. Binney Street Project, as it is known, will boast about 1.72 million square feet of office/laboratory space and other mixed uses. Alexandria Real Estate Equities, which is overseeing the project, said that all five facilities will be LEED certifiable, and Alexandria will preserve historic buildings already present on the 11.3-acre site. The new labs will be located near Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, the Broad Institute and Harvard University.

"The Binney Street Project is one of the most important developments of its kind and will further enhance Cambridge's position as a world leading center for life science research and development," says Alexandria's Senior Vice President and Regional Market Director Tom Andrews in a statement. The firm has yet to announce a construction start date or main tenant for the new park.

- here's Alexandria's release
- read the Boston.com report for more

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.